Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study)

Am J Cardiol. 2011 Nov 1;108(9):1289-96. doi: 10.1016/j.amjcard.2011.06.044.

Abstract

The aims of the present study were to estimate the prevalence of heart failure (HF) with preserved ejection fraction (HF-PEF) in patients with HF and to compare their clinical characteristics with those with reduced ejection fraction in non-Western countries. The left ventricular ejection fraction ≥ 45% if measured < 1 year before the visit was used to qualify the patients as having HF-PEF. Of the 2,536 consecutive outpatients with HF, 1990 (79%) had the EF values recorded. Of these patients, 1291 had HF-PEF, leading to an overall prevalence of 65% (95% confidence interval 63% to 67%). Compared to the patients with HF and a reduced ejection fraction, those with HF-PEF were more likely to be older (65 vs 62 years, p < 0.001), female (50% vs 28%, p < 0.001), and obese (39% vs 27%, p < 0.001). They more frequently had a history of hypertension (78% vs 53%, p < 0.001) and atrial fibrillation (29% vs 24%, p = 0.03) and less frequently had a history of myocardial infarction (21% vs 44%, p < 0.001). Only 29% of patients with HF-PEF and hypertension had optimal blood pressure control. Left ventricular hypertrophy was less frequent in those with HF-PEF (58% vs 69%, p < 0.001). The prevalence of HF-PEF was lower in the Middle East (41%), where coronary artery disease was more often found than in Latin America (69%) and North Africa (75%), where the rate of hypertension was greater. In conclusion, in the present diverse non-Western study, HF-PEF represented almost 2/3 of all HF cases in outpatients. HF-PEF mostly affects older patients, women, and the obese. Hypertension was the most frequently associated risk factor, highlighting the need for optimal blood pressure control.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Africa, Northern / epidemiology
  • Age Distribution
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Atrial Fibrillation / epidemiology
  • Cardiomyopathies / epidemiology
  • Coronary Artery Disease / epidemiology
  • Cross-Sectional Studies
  • Diuretics / therapeutic use
  • Female
  • Heart Failure / epidemiology*
  • Heart Rate
  • Humans
  • Hypertension / epidemiology
  • Hypertrophy, Left Ventricular / epidemiology
  • Latin America / epidemiology
  • Male
  • Middle Aged
  • Middle East / epidemiology
  • Mineralocorticoid Receptor Antagonists
  • Myocardial Infarction / epidemiology
  • Obesity / epidemiology
  • Prevalence
  • Sex Distribution
  • Stroke Volume*

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Diuretics
  • Mineralocorticoid Receptor Antagonists